Flulaval is the company’s older flu drug, which has been to some extent superceded by Relenza – but FDA inspectors noted “deviations from current good manufacturing practice (CGMP) requirements” in its production at GSK’s plant in Quebec.
Continue to read here
No comments:
Post a Comment